Author/Authors :
Lee, Sul Department of Obstetrics and Gynecology - School of Medicine - Pusan National University, Busan, South Korea , Lee, Hyun Joo Department of Obstetrics and Gynecology - School of Medicine - Pusan National University, Busan, South Korea , Choi, Kyung Un Biomedical Research Institute - Pusan National University Hospital, Busan, South Korea , Kwon, Byung Su Department of Obstetrics and Gynecology - School of Medicine - Pusan National University, Busan, South Korea , Suh, Dong Soo Department of Obstetrics and Gynecology - School of Medicine - Pusan National University, Busan, South Korea , Jeong, Dae Hoon Department of Obstetrics and Gynecology - Busan Paik Hospital - Inje University College of Medicine, Busan, South Korea , Kim, Geun Joo Department of Obstetrics and Gynecology - College of Medicine - Kosin University Gospel Hospital -, Kosin University, Busan, South Korea , Lee, Tae Hwa Department of Obstetrics and Gynecology - College of Medicine - Kosin University Gospel Hospital -, Kosin University, Busan, South Korea , Roh, Hyun‑Jin Department of Obstetrics and Gynecology - Ulsan University Hospital - University of Ulsan College of Medicine, Ulsan, South Korea , Kim, Ki Hyung Department of Obstetrics and Gynecology - School of Medicine - Pusan National University, Busan, South Korea
Abstract :
Background: Serous adenocarcinoma of the uterine cervix is an extremely rare variant of cervical adenocarcinoma. This study aimed
to evaluate the clinicopathological and molecular features and outcomes of serous adenocarcinoma of the uterine cervix (SACC).
Materials and Methods: This was a retrospective study conducted based on the clinical and pathological data of seven patients
diagnosed with SACC after hysterectomy, who were evaluated at the gynecologic oncologic centers between 2010 and 2019.
Results: Five cases were diagnosed at Stage IB and two at Stage IV. All patients underwent radical hysterectomy with bilateral
salpingo‑oophorectomy and subsequently received postoperative radiotherapy or chemotherapy. One patient showed persistent
disease, and two patients suffered recurrence. Immunohistochemical study showed that three (43%) of the seven patients were positive
for p53, and among these three patients, two with diffuse strong p53 expression experienced an aggressive course with recurrences
at pelvic lymph nodes, lung, and brain. Conclusion: High p53 expression and advanced stage may be associated with poorer clinical
outcomes in SACC, which suggest that immunohistochemistry may contribute to the prediction of prognosis.
